Current treatment strategies in Hodgkin lymphomas

Current Opinion in Oncology

Volumn 24, Issue 5, 2012, Pages 466-474

  Copeland, Amanda ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

conventional therapy; Hodgkin lymphoma; novel therapy

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; AZACITIDINE; BLEOMYCIN; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ENTINOSTAT; ETOPOSIDE; EVEROLIMUS; HISTONE DEACETYLASE INHIBITOR; IFOSFAMIDE; LENALIDOMIDE; MOCETINOSTAT; MONOCLONAL ANTIBODY; PANOBINOSTAT; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; EVENT FREE SURVIVAL; FATIGUE; HODGKIN DISEASE; HUMAN; LUNG TOXICITY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; HODGKIN DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84865472329     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835689a3     Document Type: Review

References (73)

1. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned. N Engl J Med 2011; 365:203-212
2. von Tresckow B, Plütschow A, Fuchs M, et al. Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial. J Clin Oncol 2012; 30:907-913.
3. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363:640-652.
4. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9:15-27.
5. Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2002; 99:618-626. (Pubitemid 34533100)
6. Oki Y, Younes A. Does Rituximab Have a Place in Treating Classic Hodgkin Lymphoma? Curr Hematol Malig Rep2010; 5:135-139.
7. Kasamon YL, Jacene HA, Gocke CD, et al. A phase II study of rituximab-ABVD in classical Hodgkin lymphoma. Blood 2012; 119:4129-4132.
8. Katz J, Janik JE, Younes A. Brentuximab Vedotin (SGN-35). Clin Cancer Res 2011; 17:6428-6436.
9. Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov 2012; 11:19-20.
10. Younes A, Connors JM, Park SI, et al. Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma [abstract 955]. In: ASH Annual Meeting Abstracts 118; 2011.
11. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive highdose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97:616-623. (Pubitemid 32113392)
12. Filmont J-E, Gisselbrecht C, Cuenca X, et al. The impact of pre and posttransplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 2007; 110:1361-1369. (Pubitemid 47435610)
13. Schot BW, Zijlstra JeM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007; 109:486-491. (Pubitemid 46105942)
14. Fanale M, Fayad L, Pro B, et al. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol 2011; 154:284-286.
15. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982; 299:65-67. (Pubitemid 12049770)
16. Younes A. CD30-targeted antibody therapy. Curr Opin Oncol 2011; 23:587-593.
17. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363:1812-1821.
18. Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. Clin Cancer Res 2012; 18:248-255.
19. Younes A, Gopal AK, Smith SE, et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. J Clin Oncol 2012; 30:2183-2189.
20. Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007; 18:1071-1079. (Pubitemid 47053777)
21. Rothe A, Younes A, Reiners KS, et al. A Phase I Study with the Bispecific Anti-CD30 x Anti-CD16A Antibody Construct AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma [abstract 3709]. In: ASH Annual Meeting Abstracts 118; 2011.
22. Heider U, Kaiser M, Sterz J, et al. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol 2006; 76:42-50.
23. Wang S, Yan-Neale Y, Cai R, et al. Activation of Mitochondrial Pathway is Crucial for Tumor Selective Induction of Apoptosis by LAQ824. Cell Cycle 2006; 5:1662-1668. (Pubitemid 44285253)
24. Brogdon JL, Xu Y, Szabo SJ, et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007; 109:1123-1130. (Pubitemid 46220659)
25. Prince HM, Bishton MJ, Harrison SJ. Clinical Studies of Histone Deacetylase Inhibitors. Clin Cancer Res 2009; 15:3958-3969.
26. Buglio D, Mamidipudi V, Khaskhely NM, et al. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. Br J Haematol 2010; 151:387-396.
27. Buglio D, Georgiakis GV, Hanabuchi S, et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008; 112:1424-1433.
28. Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011; 12:1222-1228.
29. Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study. J Clin Oncol 2012; 30:2197-2203.
30. Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007; 8:239-245. (Pubitemid 46745373)
31. + T cells in Hodgkin lymphoma. Blood 2007; 110:3226-3233. (Pubitemid 350106315)
32. Yamamoto R, Nishikori M, Kitawaki T, et al. PD-1/PD-1-Ligand Interaction Contributes to Immunosuppressive Microenvironment of Hodgkin Lymphoma [abstract 379]. In: ASH Annual Meeting Abstracts 110; 2007.
33. Ito T, Wang YH, Duramad O, et al. OX40 ligand shuts down IL-10-producing regulatory T cells. Proc Natl Acad Sci USA 2006; 103:13138-13143. (Pubitemid 44338929)
34. + T cells. J Immunol 2007; 179:1427-1430.
35. + Tregs. Blood 2007; 110:2501-2510. (Pubitemid 47523172)
36. Buglio D, Khaskhely NM, Voo KS, et al. HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood 2011; 117:2910-2917.
37. Gough MJ, Weinberg AD. OX40 (CD134) and OX40L. Adv Exp Med Biol 2009; 647:94-107.
38. Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 2004; 4:420-431. (Pubitemid 38745554)
39. Redmond WL, Ruby CE, Weinberg AD. The role of OX40-mediated costimulation in T-cell activation and survival. Crit Rev Immunol 2009; 29:187-201.
40. + Th cell antitumor immunity in mice. J Clin Invest 2007; 117:3330-3338. (Pubitemid 350096989)
41. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007; 26:1351-1356. (Pubitemid 46328465)
42. Kirschbaum MH, Goldman BH, Zain JM, et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma 2012; 53:259-262.
43. Zhou N, Moradei O, Raeppel S, et al. Discovery of N-(2-Aminophenyl)-4- [(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an Orally Active Histone Deacetylase Inhibitor. J Med Chem 2008; 51:4072-4075. (Pubitemid 352032434)
44. Fournel M, Bonfils C, Hou Y, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008; 7:759-768. (Pubitemid 351551029)
45. Harrison SJ, Hsu AK, Neeson PJ, et al. Biomarker analysis of pivotal phase II study of oral panobinostat (PAN) in relapsed/refractory Hodgkin lymphoma (HL) patients following autologous stem cell transplant (ASCT) [abstract 8046]. In: ASCO Meeting Abstracts 29; 2011.
46. Lemoine M, Derenzini E, Buglio D, et al. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood 2012; 119:4017-4025.
47. Younes A, Copeland A, Fanale MA, et al. Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma [abstract 3718]. In: ASH Annual Meeting Abstracts 118; 2011
48. Jona A, Khaskhely N, Buglio D, et al. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Exp Hematol 2011; 39:1007-1017.
49. Younes A, Hernandez F, Bociek RG, et al. The HDAC Inhibitor Entinostat (SNDX-275) Induces Clinical Responses in Patients with Relapsed and Refractory Hodgkin's Lymphoma: Results of ENGAGE-501 Multicenter Phase 2 Study [abstract 2715]. In: ASH Annual Meeting Abstracts 118; 2011.
50. Ihle NT, Powis G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 2009; 8:1-9.
51. Franke TF. PI3K/Akt: getting it right matters. Oncogene 2008; 27:6473-6488.
52. Georgakis GV, Yazbeck VY, Li Y, et al. The mTOR Inhibitor Temsirolimus (CCI-779) Induces Cell Cycle Arrest and Autophagy in Hodgkin Lymphoma (HL) Cell Lines and Enhances the Effect of the PI3-Kinase Inhibitor LY294002 [abstract 2259]. In: ASH Annual Meeting Abstracts 108; 2006.
53. Georgakis GV, Li Y, Rassidakis GZ, et al. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol 2006; 132:503-511. (Pubitemid 43381621)
54. Jundt F, Raetzel N, Müller C, et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein Î2 and NF-Î8B activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005; 106:1801-1807. (Pubitemid 41208597)
55. Zheng Y, Collins SL, Lutz MA, et al. A Role for Mammalian Target of Rapamycin in Regulating T Cell Activation versus Anergy. J Immunol 2007; 178:2163-2170. (Pubitemid 46233414)
56. Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al. Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus. Cancer Res 2006; 66:5549-5554. (Pubitemid 43927103)
57. Johnston PB, Pinter-Brown L, Rogerio J, et al. Open-Label, Single-Arm, Phase II Study of Everolimus in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma [abstract 2717]. In: ASH Annual Meeting Abstracts 118; 2011.
58. Kumar S, Mikhael JR, LaPlant BR, et al. Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies [abstract 2682]. In: ASH Annual Meeting Abstracts 118; 2011.
59. Aldinucci D, Gloghini A, Pinto A, et al. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2011; 221:248-263.
60. Baus D, Pfitzner E. Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells. Int J Cancer 2006; 118:1404-1413.
61. Holtick U, Vockerodt M, Pinkert D, et al. STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia 2005; 19:936-944. (Pubitemid 40862003)
62. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99:4283-4297. (Pubitemid 34627193)
63. Rui L, Emre NCT, Kruhlak MJ, et al. Cooperative Epigenetic Modulation by Cancer Amplicon Genes. Cancer Cell 2010; 18:590-605.
64. Derenzini E, Lemoine M, Buglio D, et al. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J 2011; 1:1-11.
65. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116:3268-3277.
66. Marzec M, Zhang Q, Goradia A, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA 2008; 105:20852-20857.
67. Yamamoto R, Nishikori M, Tashima M, et al. B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma. Cancer Sci 2009; 100:2093-2100.
68. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206:3015-3029.
69. Yamamoto R, Nishikori M, Kitawaki T, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008; 111:3220-3224.
70. Younes A, Fanale MA, McLaughlin P, et al. Phase I Study of a Novel Oral JAK-2 Inhibitor SB1518 In Patients with Relapsed Lymphoma: evidence of clinical and Biologic activity in multiple lymphoma subtypes [abstract 2830]. In: ASH Annual Meeting Abstracts 116; 2010.
71. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009; 2:36.
72. Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011; 118:5119-5125.
73. Kuruvilla J, Taylor D, Wang L, et al. Phase II Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts) 2008; 112:3052.